ArticleFrontiers in oncology2025

Case Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma.

Asako Yanagisawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.